\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Preface}{}% 2
\BOOKMARK [0][-]{chapter*.3}{Table of Contents}{}% 3
\BOOKMARK [0][-]{chapter*.4}{List of Tables}{}% 4
\BOOKMARK [0][-]{chapter*.5}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.6}{List of Abbreviations}{}% 6
\BOOKMARK [0][-]{chapter*.7}{Acknowledgments}{}% 7
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{1.1 The emergence of precision oncology}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.2}{1.2 Overview of next-generation sequencing technologies}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.2.1}{1.2.1 Illumina sequencing}{section.1.2}% 11
\BOOKMARK [2][-]{subsection.1.2.2}{1.2.2 Clinical applications of NGS}{section.1.2}% 12
\BOOKMARK [1][-]{section.1.3}{1.3 Variant analysis pipeline}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.3.1}{1.3.1 Quality control and pre-processing of raw data}{section.1.3}% 14
\BOOKMARK [2][-]{subsection.1.3.2}{1.3.2 Read alignment and post-alignment processing}{section.1.3}% 15
\BOOKMARK [2][-]{subsection.1.3.3}{1.3.3 Variant calling}{section.1.3}% 16
\BOOKMARK [2][-]{subsection.1.3.4}{1.3.4 Variant annotation}{section.1.3}% 17
\BOOKMARK [2][-]{subsection.1.3.5}{1.3.5 Variant interpretation and reporting}{section.1.3}% 18
\BOOKMARK [1][-]{section.1.4}{1.4 ACCE model process for evaluating genetic tests}{chapter.1}% 19
\BOOKMARK [1][-]{section.1.5}{1.5 Clinical implications of germline alterations in cancer}{chapter.1}% 20
\BOOKMARK [2][-]{subsection.1.5.1}{1.5.1 Cancer predisposition}{section.1.5}% 21
\BOOKMARK [2][-]{subsection.1.5.2}{1.5.2 Pharmacogenomics}{section.1.5}% 22
\BOOKMARK [1][-]{section.1.6}{1.6 Technical challenges in implementing germline testing in clinical oncology}{chapter.1}% 23
\BOOKMARK [2][-]{subsection.1.6.1}{1.6.1 Tumour-only sequencing}{section.1.6}% 24
\BOOKMARK [2][-]{subsection.1.6.2}{1.6.2 Formalin-fixed paraffin-embedded tumours}{section.1.6}% 25
\BOOKMARK [1][-]{section.1.7}{1.7 Objectives}{chapter.1}% 26
\BOOKMARK [0][-]{chapter.2}{2 Materials and Methods}{}% 27
\BOOKMARK [1][-]{section.2.1}{2.1 Overview of study design}{chapter.2}% 28
\BOOKMARK [1][-]{section.2.2}{2.2 Patient samples}{chapter.2}% 29
\BOOKMARK [1][-]{section.2.3}{2.3 Sample preparation, library construction, and Illumina sequencing}{chapter.2}% 30
\BOOKMARK [1][-]{section.2.4}{2.4 OncoPanel \(Amplicon-based targeted sequencing panel for solid tumours\)}{chapter.2}% 31
\BOOKMARK [1][-]{section.2.5}{2.5 Variant calling pipeline}{chapter.2}% 32
\BOOKMARK [2][-]{subsection.2.5.1}{2.5.1 Read alignment and variant calling}{section.2.5}% 33
\BOOKMARK [2][-]{subsection.2.5.2}{2.5.2 Variant filtering}{section.2.5}% 34
\BOOKMARK [2][-]{subsection.2.5.3}{2.5.3 Variant annotation and interpretation}{section.2.5}% 35
\BOOKMARK [1][-]{section.2.6}{2.6 Sequence analysis}{chapter.2}% 36
\BOOKMARK [1][-]{section.2.7}{2.7 Application of VAF thresholds to separate germline alterations from somatic mutations}{chapter.2}% 37
\BOOKMARK [0][-]{chapter.3}{3 Assessment of Formalin-Induced DNA Damage in FFPE Specimens}{}% 38
\BOOKMARK [1][-]{section.3.1}{3.1 Comparison of efficiency in amplicon enrichment and sequencing results between blood and FFPE specimens}{chapter.3}% 39
\BOOKMARK [1][-]{section.3.2}{3.2 Reduced coverage depth in FFPE specimens is more pronounced for longer amplicons}{chapter.3}% 40
\BOOKMARK [1][-]{section.3.3}{3.3 Deamination effects lead to increased C>T/G>A transitions in FFPE specimens}{chapter.3}% 41
\BOOKMARK [1][-]{section.3.4}{3.4 Increased age of paraffin block results in reduced amplicon yield and elevated level of C>T/G>A sequence artifacts}{chapter.3}% 42
\BOOKMARK [0][-]{chapter.4}{4 Identification of Germline Alterations in FFPE Tumours}{}% 43
\BOOKMARK [1][-]{section.4.1}{4.1 Frequency and variant assessment of germline alterations in patients from TOP cohort}{chapter.4}% 44
\BOOKMARK [1][-]{section.4.2}{4.2 Germline alterations are highly concordant between blood and FFPE specimens}{chapter.4}% 45
\BOOKMARK [1][-]{section.4.3}{4.3 Application of tumour content to separate germline alterations from somatic mutations in tumour-only analyses}{chapter.4}% 46
\BOOKMARK [0][-]{chapter.5}{5 Discussion}{}% 47
\BOOKMARK [0][-]{chapter.6}{6 Conclusion}{}% 48
\BOOKMARK [0][-]{chapter*.39}{Bibliography}{}% 49
\BOOKMARK [0][-]{appendix.A}{A Supporting Materials}{}% 50
